The Quiet Tension of Time in Immuno-Oncology

The Quiet Tension of Time in Immuno-Oncology

One of the quiet tensions in immuno-oncology is time - the time it takes for an immune system to respond meaningfully. Immune systems do not respond on demand. They don’t obey treatment calendars, scan schedules, or institutional urgency. Yet we repeatedly ask them to prove efficacy on timelines designed for what we perceive to be “a good time to respond.”

As a clinician, I understand why we use early signals: they guide decisions, shape expectations, and influence whether treatment continues or stops. Scientifically, traditional response criteria like RECIST were built for therapies, like chemotherapy, that directly kill tumor cells, where size reduction correlates predictably with cytotoxic effect.

Immunotherapy behaves differently. As noted in immune-modified response frameworks such as iRECIST and irRC, immune checkpoint inhibitors can produce atypical response patterns, including pseudoprogression, where tumors appear to enlarge initially because of immune cell infiltration rather than actual tumor growth. These patterns challenge conventional measures of early response.

Pseudoprogression may not be common, but it is real in immuno-oncology. It typically occurs early during the course of immune therapy, often around the first or second follow-up imaging timepoint, and reflects immune activation rather than treatment failure.

Yet when we judge response too early, especially using criteria designed for cytotoxic agents, we risk categorizing engagement as failure. In clinical trials and practice, this can lead to premature discontinuation of therapies that might have produced durable benefits had they been given the chance to align with the biology of immune activation.

The immune response unfolds over distinct biological phases:

  • Initial activation: immune cells recognize tumor antigens and expand.

  • Effector engagement: immune cells infiltrate the tumor microenvironment.

  • Tumor remodeling: immune-mediated effects alter tumor size and composition over time.

This complexity means early imaging changes can be ambiguous. A lesion that enlarges on scan may be a combination of tumor, infiltrating lymphocytes, edema, and remodeling - not simply unchecked progression.

There’s also variability in response across tumor types and immune contexts, and this biological noise confounds early assessment. Emerging research into immune predictors and multi-omic signatures may help distinguish true lack of response from delayed but meaningful immune engagement, but these tools are still under development.

In practice, I’ve seen patients who appeared to progress early, only for subsequent imaging or clinical stabilization to show meaningful benefit. The danger in early judgment isn’t just stopping a potentially effective therapy. It’s training ourselves to distrust slow biology and to prefer immediacy over coherence, and speed over stability.

This isn’t an argument for unbounded patience. Immune treatments can fail, and they can destabilize systems that are already fragile. The skill is in distinguishing true progression, where disease continues unchecked, from transitional perturbations that are part of the immune system’s re-education and engagement. Serial assessments, clinical context, symptomology and integrated metrics matter more than a single early snapshot.

The question isn’t whether immune therapies can show early effects. They can. The question is whether the frameworks we use to judge them early actually capture what immune systems do.

If we don’t allow for immune timelines, we risk confusing adaptation for failure and wondering why our most promising treatments appear inconsistent.

We may have looked too soon.

References:

Back to Articles

Leave a comment

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

You may also like

Blog post

Give your customers a summary of your blog post